Abstract
Despite its being a relatively common virus, the study of human papillomavirus infection has lagged behind that of other viruses. Human papillomaviruses do not provoke strong systemic antibody or T-cell responses. Furthermore, the majority of those infected do not display clinical symptoms and are able to clear the virus by unknown mechanisms. In the last decade, however, research into human papillomavirus immunology has blossomed, for two main reasons. First, there is strong circumstantial evidence that the immune system can control papillomavirus infection, since the prevalence of human papillomavirus-associated neoplasia is increased in immunocompromised individuals. Second, the strong association between human papillomavirus infection and cervical cancer has led to attempts to develop prophylactic or therapeutic vaccines. In this chapter, our current knowledge of human papillomavirus immune responses will be reviewed, and how this relates to clinical practice will be discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Best Practice & Research Clinical Obstetrics & Gynaecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
